PALISADE BIO INC (PALI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.16-7.20%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PALI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026.
Stated in 2 of 2 supplied quarters. Management reported: “During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026.” “The Company also intends to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Phase 2 ASCENTRA-CD trial of PALI-2108 in the second half of 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026.”
“EXHIBIT 99.1 Recent Highlights and Anticipated Milestones • Completed Phase 1a/b for PALI-2108, Reported Positive Data ✓ Favorable safety and tolerability profile ✓ Evidence of target engagement in i…”
As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents and believes its existing cash resources are sufficient to fund operations through major clinical development mileston…
Stated in 2 of 2 supplied quarters. Management reported: “As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents and believes its existing cash resources are sufficient to fund operations through major clinical development milestones, including the anticipated primary efficacy readout from the Phase 2 ASCENTRA-UC EXHIBIT 99.1 trial expected in the second half of 2027 and the planned primary efficacy readout from the Phase 2 ASCENTRA-CD trial expected in early 2028.”
“As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents and believes its existing cash resources are sufficient to fund operations through major clinical development mileston…”
“As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones…”
Recent Highlights • Strengthened the Board of Directors with the appointments of biopharmaceutical industry veterans Robert Baltera and Jordan Zwick, adding expertise across biotechnology leadership,…
Stated in 1 of 2 supplied quarters. Management reported: “Recent Highlights • Strengthened the Board of Directors with the appointments of biopharmaceutical industry veterans Robert Baltera and Jordan Zwick, adding expertise across biotechnology leadership, strategic transactions and capital markets as the Company advances PALI-2108 into Phase 2 development.”
“Recent Highlights • Strengthened the Board of Directors with the appointments of biopharmaceutical industry veterans Robert Baltera and Jordan Zwick, adding expertise across biotechnology leadership,…”
Progress PALI-2108 through Phase 2 clinical trials for ulcerative colitis and Crohn's disease with key efficacy readouts expected in 2027 and 2028.
Ensure sufficient cash resources to support operations through major clinical development milestones including Phase 2 trial readouts in 2027 and 2028.
Over the trailing year it converted 0.66x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.